doi: 10.1128/AAC.43.10.2513.
Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones
Affiliations
- PMID: 10508034
- PMCID: PMC89510
- DOI: 10.1128/AAC.43.10.2513
Item in Clipboard
Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones
Antimicrob Agents Chemother.
1999 Oct.
Abstract
The parC and gyrA genes of 73 ciprofloxacin-resistant and 6 ciprofloxacin-susceptible Enterococcus faecium clinical isolates were partly sequenced. Alterations in ParC and GyrA, possibly in combination with other resistance mechanisms, severely restricted the in vitro activities of the nine quinolones tested. For all isolates, clinafloxacin and sitafloxacin showed the best activities.
Similar articles
-
Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium.Antimicrob Agents Chemother. 1999 Apr;43(4):947-9. doi: 10.1128/AAC.43.4.947. Antimicrob Agents Chemother. 1999. PMID: 10103206 Free PMC article.
-
DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.Antimicrob Agents Chemother. 1998 Nov;42(11):2810-6. doi: 10.1128/AAC.42.11.2810. Antimicrob Agents Chemother. 1998. PMID: 9797208 Free PMC article.
-
Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.Antimicrob Agents Chemother. 2001 Mar;45(3):734-8. doi: 10.1128/AAC.45.3.734-738.2001. Antimicrob Agents Chemother. 2001. PMID: 11181352 Free PMC article.
-
Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.Antimicrob Agents Chemother. 2001 Aug;45(8):2263-8. doi: 10.1128/AAC.45.8.2263-2268.2001. Antimicrob Agents Chemother. 2001. PMID: 11451683 Free PMC article.
-
Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.Antimicrob Agents Chemother. 1999 Feb;43(2):329-34. doi: 10.1128/AAC.43.2.329. Antimicrob Agents Chemother. 1999. PMID: 9925527 Free PMC article.
Cited by
-
Virulence gene detection and antimicrobial resistance analysis of Enterococcus faecium in captive giant pandas (Ailuropoda melanoleuca) in China.Acta Vet Scand. 2023 Feb 3;65(1):4. doi: 10.1186/s13028-023-00668-z. Acta Vet Scand. 2023. PMID: 36737784 Free PMC article.
-
Automated ribotyping of vancomycin-resistant Enterococcus faecium isolates.J Clin Microbiol. 2002 Jun;40(6):1977-84. doi: 10.1128/JCM.40.6.1977-1984.2002. J Clin Microbiol. 2002. PMID: 12037051 Free PMC article.
-
Gatifloxacin: a review of its use in the management of bacterial infections.Drugs. 2002;62(1):169-207. doi: 10.2165/00003495-200262010-00007. Drugs. 2002. PMID: 11790160 Review.
-
High-level ciprofloxacin resistance from point mutations in gyrA and parC confined to global hospital-adapted clonal lineage CC17 of Enterococcus faecium.J Clin Microbiol. 2006 Mar;44(3):1059-64. doi: 10.1128/JCM.44.3.1059-1064.2006. J Clin Microbiol. 2006. PMID: 16517894 Free PMC article.
-
Association of mutation patterns in GyrA and ParC genes with quinolone resistance levels in lactic acid bacteria.J Antibiot (Tokyo). 2015 Feb;68(2):81-7. doi: 10.1038/ja.2014.113. Epub 2014 Sep 10. J Antibiot (Tokyo). 2015. PMID: 25204345
References
-
- Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother. 1997;40:639–651. - PubMed
-
- Eliopoulos G M. Increasing problems in the therapy of enterococcal infections. Eur J Clin Microbiol Infect Dis. 1993;12:409–412. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
